Nutrition and behavior change remain foundational, whether someone chooses to use a GLP-1 or not. In the first nine months of 2025, major pharmaceutical companies spent more than $700 million advertising GLP-1 medications2, with Eli Lilly spending approximately $34 million on television spots in January 2026.3 Yet the 2026 Virta Vitals report suggests that growing awareness of GLP-1s has not necessarily translated into greater willingness to use them
Choosing the Right Weight Loss Program for You in Louisiana For many adults in Louisiana, managing weight can feel challenging without consistent medical guidance
UNDERSTANDING SEMAGLUTIDE, OZEMPIC, and WEGOVY Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist medication that is prescribed under the brand names Ozempic and Wegovy
IFN--signals activate the intracellular JAK-signal transducer and activator (STAT) 1 pathway to produce CXCL9/10 in keratinocytes, after which cytotoxic T cells expressing the receptor CXCR3 migrate to the epidermis and release molecules, such as granzyme B and perforin, to attack melanocytes
The medication may not remain stable once the pen is opened, and measuring a partial dose accurately becomes difficult, raising the risk of receiving either too much or too little active compound
A physician might report code 99213-25 with diagnosis code E11.9 in addition to the appropriate flu vaccine and administration codes